Growing Advancements in Life Science Research to Expand Oligonucleotide Synthesis Market: Fact MR Study forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business From Novasep pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
January 28, 2021
January 28, 2021 | New products for high-content imaging, virus reagents and enrichment, software for small molecule design, and pharmacokinetic simulation. Plus: acquisitions in drug discovery services and partnerships for data analysis, single cell analysis, machine learning, and more.
Certara has released
version 20 of its Simcyp Physiologically-based Pharmacokinetic (PBPK) Simulator platform. Simcyp PBPK Simulator version 20 offers new and enhanced models for maternal health, such as assessing drug performance during pregnancy and lactation. It also automates the assessment of virtual bioequivalence to attain biowaivers and analyzes drugs delivered via long-acting injectable delivery. Additional upgrades have been made to the Simcyp PBPK Simulator’s animal, liver, absorption, and skin models. Press release.
LaingBuisson News
Thermo Fisher Scientific, the worldâs largest maker of scientific instruments, is to acquire Belgian viral vector manufacturing business Henogen for â¬725m (US$880.3m) in cash. A subsidiary of Groupe Novasep, Henogen provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers from two locations in Seneffe and Gosselies. Founded more than…
You must be a HMI Subscriber to view this content.
Adrian Murdoch has more than 25 yearsâ experience as an international journalist. He started his career at World Link, the magazine of the World Economic Forum. He covered debt capital markets for Reuters in Singapore throughout the Asian Financial Crisis, and then the European Central Bank in Frankfurt. Most recently he covered healthcare markets in Southeast Asia and worldwide. As a freelancer he has worked for Forbes, The Wall Street Journal, Euromoney, the Scotsman and the BBC. The author of a